Experimental data on anti-MIF and anti-APP oncotherapy already exists, with vaccination targeting of APP being discussed as a therapy for several cancers [37] and anti-MIF treatment having potential for treatment of undifferentiated pleomorphic sarcoma [43]. The gene discussed is MIF; the disease is undifferentiated pleomorphic sarcoma.